Lipid-lowering efficacy of 3,4-Di(OH)-phenylpropionic L-leucine in high-cholesterol fed rats

Journal of Biochemical and Molecular Toxicology

Volumn 19, Issue 1, 2005, Pages 25-31

  Kim, Soon Ja ^a   Bok, Song Hae ^b   Lee, SangKu ^b   Lee, Mi Kyung ^a   Park, Yong Bok ^a   Kim, Hye Jin ^a   Choi, Myung Sook ^a  

^a Kyungpook National University   (South Korea)

^b Korea Research Institute of Bioscience and Biotechnology (KRIBB)   (South Korea)

Author keywords

3,4 Di(OH) hydrocinnamate; 3,4 Di(OH) phenylpropionic; High Cholesterol Diet; L Leucine amide

Indexed keywords

3,4 DIHYDROXYPHENYLPROPIONYLLEUCINAMIDE; CHOLESTEROL; CHOLESTEROL ACYLTRANSFERASE; DIHYDROCAFFEIC ACID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; POLYPHENOL DERIVATIVE; PROTEIN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL DIET; CHOLESTEROL LIVER LEVEL; CONTROLLED STUDY; DIET SUPPLEMENTATION; DRUG EFFECT; DRUG EFFICACY; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME INHIBITION; MALE; NONHUMAN; RAT; STRUCTURE ACTIVITY RELATION; TRIACYLGLYCEROL BLOOD LEVEL;

ANIMAL FEED; ANIMALS; CAFFEIC ACIDS; CHOLESTEROL, DIETARY; FECES; HYDROXYMETHYLGLUTARYL COA REDUCTASES; LEUCINE; LIPID METABOLISM; LIPIDS; LIVER; MALE; MOLECULAR STRUCTURE; ORGAN SIZE; RATS; RATS, SPRAGUE-DAWLEY; STEROLS; WEIGHT GAIN;

EID: 14644445260     PISSN: 10956670     EISSN: None     Source Type: Journal    
DOI: 10.1002/jbt.20054     Document Type: Article

References (48)

1. Law MR, Wald NJ. An ecological study of serum cholesterol and ischaemic disease between 1950 and 1990. Eur J Clin Nutr 1994;48:305-325.
2. Wald NJ, Law MR. Serum cholesterol and ischaemic heart disease. Atherosclerosis 1995;118:1-5.
3. Kesäniemi YA, Miettinen TA. Cholesterol absorption efficiency regulates plasma cholesterol level in the Finnish population. Eur J Clin Invest 1973;17:391-395.
4. Hlgerud P, Saarem K, Norum KR. Acyl-CoA: Cholesterol acyltransferase in human small intestine: Its activity and some properties of the enzyme reaction. J Lipid Res 1981;22:271-277.
5. Suckling KE, Stange EF. Role of acyl-CoA: Cholesterol acyltransferase in cellular cholesterol metabolism. J Lipid Res 1985;26:647-671.
6. 14C-cholesterol absorption in animal models (abstract). FASEB J 1992;6:1388.
7. Clark DE, Commons TJ, Prozialeck DH, McKean ML, Adelman SJ. Inhibition of hypercholesterolemia by specific pancreatic cholesterol esterase hydrolase inhibitors (abstract). FASEB J 1992;6:1388.
8. Zhang HY, Ge N, Zhang ZY. Theoretical elucidation of activity differences of five phenoic antioxidants. Chung Kuo Yao Li Hsueh Pao 1999;20:363-366.
9. Noguchi N, Niki E. Phenolic antioxidants: A rationale for design and evaluation of novel antioxidant drug for atherosclerosis. Free Radical Biol Med 2000;28:1538-1546.
10. Huff MW, Telford DE. Dietary fish oil increases the conversion of VLDL apoB. Atherosclerosis 1989;9:58-66.
11. O'Brien BC, Skutches CL, Henderson GR, Reiser R. Interrelated effects of food lipids on steroid metabolism in rats. J Nutr 1977;107:1444-1454.
12. Yugarani T, Tan BK, Teh M, Das NP. Effects of polyphenolic natural products on the lipid profiles of rats fed high fat diets. Lipids 1992;27:181-186.
13. Iwahashi H, Ishii T, Sugata R, Kido R. The effects of caffeic acid and its related catechols on hydroxyl radical formation by 3-hydroxyanthranilic acid, ferric chloride, and hydrogen peroxide. Arch Biochem Biophys 1990;276:242-247.
14. Nardini M, D'Aquino M, Tomassi G, Gentili V, Di Felice M, Scaccini C. Inhibition of human low-density lipoprotein oxidation by caffeic acid and other hydroxycinnamic acid derivatives. Free Radical Biol Med 1995;19:541-552.
15. Tanaka T, Kojima T, Kawamori T, Wang A, Suzui M, Okamoto K, et al. Inhibition of 4-nitroquinoline-1-oxide-indced rat tongue carcinogenesis by the naturally occurring plant phenolics caffeic, ellagic, chlorogenic and ferrulic acids. Carcinogenesis 1993;14:1321-1325.
16. Yamada J, Tomita Y. Antimutagenic activity of caffeic acid and related compounds. Biosci Biotechnol Biochem 1996;60:328-329.
17. Jeong-Sun Lee, Myung-Sook Choi, Seon-Min Jeon, et al. Lipid-lowering and antioxidative activities of 3,4-di(OH)-cinnamate and 3,4-di(OH)-hydrocinnamate in cholesterol-fed rats. Clin Chim Acta 2001;314:221-229.
18. Scalbert A, Williamson G. Dietary intake and bioavailability of polyphenols. J Nutr 2000;130:2073-2085.
19. American Institute of Nutrition. Report of the American Institute of Nutrition. Ad Hoc committee on standards for nutritional studies. J Nutr 1977;107:1340-1348.
20. American Institute of Nutrition. Report of Ad Hoc committee on standards for nutritional studies. J Nutr 1980;110:1717-1726.
21. Allain CC, Poon LS, Chan CSG. Enzymatic determination of total serum cholesterol. Clin Chem 1974;20:470-475.
22. Waenic RG, Albers JJ. A comprehensive evaluation of the heparin-manganese precipitation procedure for estimating a high density lipoprotein cholesterol. J Lipid Res 1978;19:65-76.
23. McGowan MW, Artiss JD, Strandbergh DR, Zak B. A peroxidase-coupled method for the colorimetric determination of serum triglycerides. Clin Chem 1983;29:538-542.
24. Folch J, Lees M, Sloane-Stanley GH. A simple method for isolation and purification of total lipids from animal tissues. J Biol Chem 1957;226:497-509.
25. Hulcher FH, Oleson WH. Simplified spectrophotometric assay for microsomal 3-hydroxy-3-methylglutaryl CoA reductase by measurement of coenzyme A. J Lipid Res 1973;14:625-631.
26. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976;72:248-254.
27. Shapiro DJ, Nordstorm JL, Mitschelen JJ, Rodwell VW, Schimke RT. Micro assay for 3-hydroxy-3-methylglutaryl-CoA reductase in rat liver and in L-cell fibroblasts. Biochim Biophy Acta 1974;370:369-377.
28. Erickson SK, Schrewsbery MA, Brooks C, Meyer DJ. Rat liver acyl-coenzyme A: Cholesterol acyltransferase: Its regulation in vivo and some of properties in vitro. J Lipid Res 1980;21:930-941.
29. Gillies PJ, Rathgeb KA, Perri MA, Robinson CS. Regulation of acyl-CoA: Cholesterol acyltransferase activity in normal and atherosclerotic rabbit aortas: Role of a cholesterol substrate pool. Exp Mol Pathol 1986;44:320-339.
30. Czubayko F, Beumers B, Lutigohann D, Bergmann K. A simplified micro-method for quantitation of fecal excretion for neutral and acidic sterols for outpatient studies in humans. J Lipid Res 1992;32:1861-1867.
31. Michael JC, Ian AM. Enzymatic determination of 3α-, 7α- and 12α hydroxyl groups of fecal bile salts. Clin Chem 1980;26:1298-1300.
32. Rifkind BM, Segal P. Lipid research clinics program reference values for hyperlipidemia and hypolipidemia. JAMA 1983;250:1869-1872.
33. Frick MH, Elo O, Haapa K, Heinonen OP, Heinsalmi P, Helo P, Huttenen JK, Kaitaniemi P, Koskinen P, Manninen V, Mäenpää H, Mälkönen M, Mänttäri M, Norola S, Pasternack A, Pikkarainen J, Romo M, Sjöblom, Nikkilä A. Helsinki Heart Study: Primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 1987;317:1237.
34. Bailey DG, Dresser GK. Interactions between grapefruit juice and cardiovascular drugs. Am J Cardiovasc Drugs 2004;4:281-297.
35. Eriksson M, Carlson LA, Miettinen TA, Angelin B. Stimulation of recal steroid excretion after infusion of recombination proapolipoprotein A-1: Potential reverse cholesterol transport in humans. Circulation 1999;100:594-598.
36. Gordon DJ, Rifkind BM. High-density lipoprotein: The clinical implications of recent studies. N Engl J Med 1989;321:1311-1316.
37. Barter PJ, Rye KA. Molecular mechanisms of reverse cholesterol transport. Curr Opin Lipidol 1996;7:82-87.
38. Tall AR. Plasma high density lipoproteins: Metabolism and relationship to atherogenesis. J Clin Invest 1990;86:379-384.
39. Fieding CJ, Fielding PE. Molecular physiology of reverse cholesterol transport. J Lipid Res 1995;36:211-228.
40. Turley SD, Dietschy JM. Sterol absorption by the small intestine. Curr Opin Lipidol 2003;14:233-240.
41. Suckling KE, Strange EF. Role of acyl-CoA: Cholesterol acyltransferase in cellular cholesterol metabolism. J Lipid Res 1985;26:647-671.
42. Chang TY, Chang CCY, Cheng D. Acy-coenzyme A: Cholesterol acyltransferase. Annu Rev Biochem 1997;66:613-638.
43. Ross R. The pathogenesis of atherosclerosis: A perspective for the 1990s. Nature 1993;362:801-809.
44. Burnett JR, Wilcox LJ, Telford DE, Kleinstiver SJ, Barrrett PH, Newton RS, Huff MW. Inhibition of ACAT by avasimibe decreases both VLDL and LDL apolipoprotein B production in miniature pigs. J Lipid Res 1999;40:1317-1327.
45. Bocan TM, Mueller SB, Brown EQ, Lee P, Bocan MJ, Rea T, Pape ME. HMG-CoA reductase and ACAT inhibitors act synergistically to lower plasma cholesterol and limit atherosclerotic lesion in the cholesterol-fed rabbit. Atherosclerosis 1998;139:21-30.
46. Hay JM, Yu WM, Ashraf T. Pharmacoeconomics of lipids-lowering agents for primary and secondary prevention of coronary artery disease. Pharmacoeconomics 1999;15:47-74.
47. Bjorkhem I. Inborn errors of metabolism with consequences for bile acid biosynthesis. Scand J Gastroenterol Suppl 1994;204:68-72.
48. Field FJ, Cooper AD, and Erickson SK. Regulation of rabbit intestinal acyl coenzyme A: Cholesterol acyltransferase in vivo and in vitro. Gasteroenterology 1982;83:873-880.